CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
Neoadjuvant Immunotherapy with Response-Adapted Treatment vs Standard-Of-Care Treatment For Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Selective Index Node Resection vs Lymph Node Dissection after Neoadjuvant Immunotherapy for Stage IIIB-D Melanoma The Multicentre Selective Lymphadenectomy Trial-3 (MSLT-3)
MA41 trial investigating a de-Escalation of adjuvant chemotherapy in HER-2 positive, estrogen receptor-negative, node-negative, early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and dual HER-2 blockade (DECRESCENDO) trial has now permanently closed.
CCTG is pleased to announce the 2025 Annual Spring Meeting of Participants, which will take place on April 25-27, 2025, at the Chelsea Hotel in Toronto.
In April 2024, at the CCTG Spring Meeting of Participants, the CCTG Patient Representative Committee members participated in a facilitated session designed to identify the research topics that Committee members view as being most important to cancer patients and caregivers. The outcome of the workshop resulted in the identification by the CCTG reps of six Cancer Research Priorities.
The Canadian Cancer Trials Group would like to extend our sincere gratitude to Erwin Wanderer, Bob Taylor, and Martina Wood for their commitment and dedication to the CCTG Patient Representative Committee. Erwin, Bob and Martina have completed their term on the committee and will be moving on from their invaluable role at CCTG at the end of 2024.
